On this day, the diagnosis of Alzheimer's baseline is clinical, which means it cannot be found until the first symptoms appear, or even later, if the neuropathic damage is already serious. Therefore, it is necessary to search for new biomarkers that allow for a strange disorder in a non-invasive way.
ALTEA responds to this challenge, a new tool made by researchers from the Universitat Politecnica de Valencia (UPV) (Spain), which belongs to the Center for Biomaterials and Tissue Engineering (CBIT), in collaboration with Dr. Enrique Mollá, radiologist at the De Ribera hospital.
The instrument – for now, in beta phase for research – helped detect Alzheimer's in its most striking phases. ALTEA gives you the ability to visualize and collapse magnetic resonance images, from these images, execute and analyze various brain-texture parameters, which cause disease in biomarkers of Alzheimer's (biomarkers are biological indicators that measure and their presence and intensity may be related to the development of a disease).
"At the light of the results we received, we confirmed that both the 2D and 3D texture analysis are very powerful tools that can improve the diagnosis of Alzheimer's disease anywhere and anywhere. ALTEA provides peace diagnosis and distinguishes the various steps of a disease, "says David Moratal, a researcher at the Center for Biomaterials and Tissue Engineering in & # 39; e UPV.
The researchers and the software. (Photo: UPV)
The software developed by & # 39; s UPV researchers does what it does is a & # 39; mathematical processing; The images, which determine some parameters, can quantify the homogeneity or heterogeneity of a hippocampal region. "With these parameters we can characterize and discover at what stage the disease is and we can help discover non-skeletal discoveries for clinical specialists," adds Rafael Ortiz, a UPV PhD student and one of & # 39; s software developers in & # 39; together with the students of the biomedical engineering diploma of & # 39; a UPV, Carlos López and Carolina Giménez.
To end the new software, the researchers examined a magnetic resonance image of three groups of people: Alzheimer's patients, patients with mild mild cognitive impairment, and control subjects. The analyzes were performed in a hippocampal region (one from & # 39; s region & # 39; s that was most affected by resin atrophy in & nbsp; an early & apos; s disease) with circles and spherical regions of interest. "EA Altea has been developed, we conducted a cross-study study using a comprehensive statistical analysis to get the predictive capacity of possible biomarkers, with very positive results," says David Moratal.
At & # 39; a request in & # 39; A clinical practice determines the researchers that & # 39; we need to set even more texture parameters, and we need to improve the module to analyze our combinations of textual parameters with automatic learning techniques to require validated classification models & # 39 ;.
At present, Alzheimer's disease (AD) is the most common type of dementia – between 60 and 80% of cases. This neurodegenerative disorder is characterized by the presence of a progressive nuisance of cognitive and behavioral functions, particularly in the preceding years. According to data from the Spanish Society of Neurology (SEN), the past 10 years have strengthened Alzheimer's over 61 percent (63.7 percent in women and 55.8 percent in men). (Source: UPV)